ProLung, Inc.

About ProLung Inc

This author has not yet filled in any details.
So far ProLung Inc has created 21 entries.

ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment

Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry.  When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology.  The non-invasive test correctly identified 23 out of 27, or 85% of patients where malignancy was confirmed by tissue biopsy.  More results are expected soon, as the EPN Scan has been administered to more than 170 patients in Europe and over 100 of these are enrolled in the registry.  Other research is underway at eight cancer centers in the US and four in Asia.

“The key to improved survival is understanding the risk associated with a suspicious pulmonary nodule.  It’s heartening to see such positive results coming from leading European interventional pulmonologists.  They are pioneers focused on immediate evaluation of indeterminate lung nodules.  Compared with the standard of care, we believe that the EPN Scan can increase the time available for treatment and may ultimately save lives,” said Steven Eror, President and CEO of ProLungdx.

The EPN Scan uses its novel mass averaging bioconductance technology to evaluate patients who discover lung nodules incidentally or by lung cancer screening.  As the low-dose computed tomography (LDCT) screen becomes widespread, risk stratification tools, such as ProLungdx’s EPN Scan, will be essential to aiding physicians to evaluate the risk of cancer while treatment options are still available.

About ProLungdx

ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung […]

By |18 May 2016|Press|Comments Off on ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment|

In March 2016, ProLungdx was featured on Rai 3, the 3rd largest National news source in the market in Italy.

By |13 April 2016|Press|Comments Off on In March 2016, ProLungdx was featured on Rai 3, the 3rd largest National news source in the market in Italy.|

ProLung study presented at IASLC 2015 Conference

September 22, 2015, Salt Lake City, Utah – A study comparing results from the ProLung EPN scan to the results of PET scans was presented at the 16th World Conference on Lung Cancer in Denver, CO 2015.  The results from this study were also published  in the Journal of Thoracic Oncology, concluding that the “EPN Scan performed favorably versus PET, especially in evaluating smaller or PET-indeterminate lesions.”  Below is the abstract of the published data:
       

  
Bioconductance Compared to 18FDG-PET in Evaluating CT-Detected Lung Lesions
Rex Yung1, Jeff O’Driscoll2, Michael Garff3, Ming Ying Zeng4

1Pulmonology, Greater Baltimore Medical Center, Townson/MD/United States of America, 2Emergency Medicine, Intermountain Health Care, Salt Lake City/UT/United States of America, 3Prolung, Salt Lake City/UT/United States of America, 4Pulmonology, Johns Hopkins School of Medicine, Baltimore/MD/United States of America

 Background: Lung cancer (LC) is the leading cause of cancer mortality. Computed tomographic (CT) screening detects LC at earlier stages but also results in finding many more smaller, benign nodules. Positron-Emission-Tomography (PET) is commonly used to evaluate suspicious lesions prior to invasive biopsies. However, PET accuracy is confounded by various factors including size, inflammation and tumor metabolic activity. Another potential biomarker of cancerous tissue is a non-invasive measure of transcutaneous bioconductance. This study compares Electro Pulmonary Nodule (EPN), a tissue bioconductance scan, to 18FDG-PET in evaluating CT detected suspicious lung lesions.

Methods: Cohort- 27 patients with suspicious nodules evaluated with both PET and EPN scanning (IRB approved protocol) prior to biopsy or long-term radiologic follow-up. An EPN Scan measuring bioconductance was performed on bilateral anatomic skin sites and results were scored as either positive or negative dependent on a defined cut-off point. The PET results were interpreted as positive, negative or indeterminate.

Results: There were 18 LCs (16 non-small […]

By |22 September 2015|Press|Comments Off on ProLung study presented at IASLC 2015 Conference|

Dr. Jeffrey S. O’Driscoll joins Board of Directors

August 20, 2015, Salt Lake City Utah – The Board of Directors of the Company appointed Jeffrey S. O’Driscoll as a director of the Company.  Dr. O’Driscoll has practiced as an emergency physician since 1992.  He started with Salt Lake Emergency Physicians and then with Utah Emergency Physicians, LLC, when Salt Lake Emergency Physicians merged with Wasatch Emergency Physicians to form the new group.   Since 2004, he has served as an Assistant Adjunct Professor at the University of Utah College of Medicine.  Since 2008, Jeffrey has served as the Medical Director of the Valley Emergency Communication Center – the 911 Call Center for Salt Lake Valley. From 2010 to 2013, he was the Chairman and CEO of Dolor Technologies, LLC, which markets and sells a device co-invented by Dr, O’Driscoll for treating severe aches.  Jeff has served as a member of the medical advisory board of the Company since 2013.   He earned a B.S. in Microbiology from Brigham Young University and an M.D. from the University of Utah College of Medicine.  He has written and presented extensively on professional and religious topics.
For additional information contact:

Chelsey Keeler
801 736 0729 (office)
info@prolungdx.com

By |21 August 2015|Press|Comments Off on Dr. Jeffrey S. O’Driscoll joins Board of Directors|

Leavitt Partners CEO McKeown joins ProLung Board of Directors

Salt Lake City, Utah (July 2, 2014) – “Rich McKeown brings a deep understanding of the healthcare industry as the chief executive of one of the nation’s most respected healthcare consulting firms,” said ProLung President and CEO Steven Eror when he announced Leavitt Partners CEO Rich McKeown as the newest member of the Company’s board of directors.

“As Chief of Staff to US Department of Health and Human Services Secretary Mike Leavitt during the George W. Bush Administration, Mr. McKeown oversaw the daily operations of the Secretary, which included managing 27 federal agencies and overseeing the largest federal departmental budget. His insights and expertise will be valuable as we enter into an exciting phase of our Company’s growth and development with the launch of distribution and sales in Europe and our continued efforts to obtain the approvals required to market in the US.”

ProLung developed a patented, highly innovative, non-invasive, non-radiating Electro Pulmonary Nodule Scan, or EPN Scan, as an aid in the diagnosis of lung cancer, the deadliest form of cancer.  In Europe, the EPN Scan is marketed as FreshMedx. In the US, the Company plans to market the EPN Scan, subject to FDA approval, as ProLung.

In well-controlled clinical testing published in the Journal of Thoracic Oncology in 2012, the EPN Scan correctly categorized patients with malignant lung lesions with a 90% accuracy rate.

“At Leavitt Partners, we collaborate with clients and through our Health Intelligence Partners forum provide a window into the future of healthcare,” said McKeown. “The ProLung EPN device and Scan is the type of pioneering medical technology that we need available in the market to save lives.”

 

About ProLung: Known as ProLung in the US and Freshmedx in Europe, the Salt Lake City-based medical technology […]

By |2 July 2014|Press|Comments Off on Leavitt Partners CEO McKeown joins ProLung Board of Directors|

ProLung names Clark Campbell as Chairman of the Board

September 11, 2012, Salt Lake City, Utah—The medical technology company, ProLung, today announced the naming current board member Clark A. Campbell, Ph.D. as its new Chairman, replacing William A. Fresh, who continues as a Director. Campbell steps into this role as the company makes preparations to market the ProLung Test, a new tool in the early detection of lung cancer. Studies have shown that the test immediately and accurately identifies malignancy in patients who have been found to have an indeterminate lung mass. This can help solve the crucial problem of late detection, a major factor in lung cancer’s high mortality rate. “Dr. Campbell’s project management expertise will be invaluable as we embark on the final stages of preparing the ProLung Test for U.S. and international markets,” said Steven C. Eror, president and CEO of ProLung. “We’re fortunate to have him join us in our efforts to help give lung cancer patients a better chance for survival.”

By |12 September 2012|Press|Comments Off on ProLung names Clark Campbell as Chairman of the Board|

Freshmedx announces name change to ProLung,TM underscoring its focus on the deadliest of cancers

September 11, 2012, Salt Lake City, Utah—Freshmedx today announced its intention to do business as ProLung, as it continues to commercialize the ProLung Test, a new tool in the early detection of lung cancer. According to company president Steven C. Eror, “The ProLung name expresses the hope this new test brings to the battle against the deadliest of all cancers. Studies have shown this new technology to be a major step forward in helping to solve the problems of late detection and difficult diagnosis, the main causes of lung cancer’s high mortality rate. ProLung reflects our commitment to promote lung health and improve outcomes for lung cancer patients.”

By |10 September 2012|Press|Comments Off on Freshmedx announces name change to ProLung,TM underscoring its focus on the deadliest of cancers|

Freshmedx Lung Cancer Diagnostic Successfully Evaluates Indeterminate Lung Masses

March 22, 2011— Freshmedx today announced the completion of a clinical trial at a major medical center in Baltimore. Freshmedx’s proprietary Computerized Bioconductance Test (CB TestTM) showed favorable results in distinguishing between benign and malignant indeterminate masses by chest CT in undiagnosed individuals with lung cancer symptoms. In this trial, the CB TestTM demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant masses confirmed by biopsy or stable disease.

Many heavy smokers and others at risk of lung cancer have lung nodules that show up on CT scans as indeterminate (unidentifiable) lung masses. Few of these are malignant, but in order to save lives, physicians must resolve diagnosis of these indeterminate masses early in order to allow for swift biopsy and therapeutic intervention. The current practice requires patients to wait months or even years for their mass to grow in order to confirm (via CT scan) the likelihood of malignancy or face an invasive or open lung biopsy.

“This technology has the potential to reduce the stressful waiting period for those who have indeterminate masses and often undergo additional CT evaluation prior to receiving biopsy,” said Karleen Callahan, Ph.D., vice president of clinical affairs for Freshmedx. “There are millions of people at high risk of lung cancer, many who are living with smaller indeterminate masses who must wait months for additional CT scanning to determine whether the mass is growing and requires biopsy. The CB Test has the potential to be administered immediately upon discovery of an indeterminate finding by CT, and helps inform the physician whether an immediate biopsy is warranted or if longer term, radiological follow-­‐up is appropriate.”

The CB TestTM is non-­‐invasive, simple to perform, involves no ionizing radiation and differs […]

By |22 March 2012|Press|Comments Off on Freshmedx Lung Cancer Diagnostic Successfully Evaluates Indeterminate Lung Masses|

Freshmedx study published in the Journal of Thoracic Oncology, the official Journal of the International Association for the Study of Lung Cancer

March 20, 2012— Freshmedx today announced that its ground-breaking study on the use of computed bioconductance technology in detecting lung cancer will be published in April edition of the Journal of Thoracic Oncology. Freshmedx’s proprietary CB Test is a non- invasive adjunctive test that can evaluate patients with lesions suspicious for lung cancer and evaluate the likelihood that indeterminate lung lesions are malignant or benign. “We are pleased to have our clinical results published in the leading lung cancer journal,” said Steve Eror, president and chief executive officer of Freshmedx. “There is an increased need for this technology, especially given the recent National Lung Screening Trial (NLST) results and the adoption of Low-dose helical CT Screening (LDCT) programs.”

By |21 March 2012|Press|Comments Off on Freshmedx study published in the Journal of Thoracic Oncology, the official Journal of the International Association for the Study of Lung Cancer|

In the “Year of the Lung,” Utah Company Freshmedx Announces Breakthrough Lung Cancer Diagnostic

February 18, 2010—In celebration of World Cancer Day and the Year of the Lung, Freshmedx today announced that it has entered into multiple discussions for the international license of its Bioconductance Scanning Platform (BSP). The BSP is a medical device that can dramatically improve the accuracy of pre-surgical lung cancer diagnosis in a simple and painless 12-minute scan. Freshmedx is pursuing regulatory approvals in the US and has completed CE mark testing for European distribution. Cancer is projected to become the leading cause of death in 2010 according to the International Agency for Research on Cancer. Of all cancers, lung cancer is by far the most deadly. It results in more deaths than breast, prostate, colon, liver, kidney and melanoma cancers combined, yet it receives only one tenth the per-patient resources of other cancers.

By |18 February 2012|Press|Comments Off on In the “Year of the Lung,” Utah Company Freshmedx Announces Breakthrough Lung Cancer Diagnostic|